177 related articles for article (PubMed ID: 22814621)
21. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
[TBL] [Abstract][Full Text] [Related]
22. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
23. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
Stauffer SR
Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
[TBL] [Abstract][Full Text] [Related]
25. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
[TBL] [Abstract][Full Text] [Related]
26. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
27. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
Huang S; Sinicrope FA
Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
[TBL] [Abstract][Full Text] [Related]
28. 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines.
Zagorodna O; Martin SM; Rutkowski DT; Kuwana T; Spitz DR; Knudson CM
Oncogene; 2012 May; 31(22):2738-49. PubMed ID: 21986940
[TBL] [Abstract][Full Text] [Related]
29. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
30. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
Ezzoukhry Z; Louandre C; François C; Saidak Z; Godin C; Mazière JC; Galmiche A
Mol Pharmacol; 2011 Jun; 79(6):997-1004. PubMed ID: 21393385
[TBL] [Abstract][Full Text] [Related]
31. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.
Allaman-Pillet N; Oberson A; Munier F; Schorderet DF
Ophthalmic Genet; 2013; 34(1-2):1-13. PubMed ID: 21955141
[TBL] [Abstract][Full Text] [Related]
32. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Reuland SN; Goldstein NB; Partyka KA; Cooper DA; Fujita M; Norris DA; Shellman YG
PLoS One; 2011; 6(8):e24294. PubMed ID: 21897876
[TBL] [Abstract][Full Text] [Related]
33. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
34. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Hauck P; Chao BH; Litz J; Krystal GW
Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
[TBL] [Abstract][Full Text] [Related]
35. Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry.
Clerc P; Carey GB; Mehrabian Z; Wei M; Hwang H; Girnun GD; Chen H; Martin SS; Polster BM
PLoS One; 2012; 7(8):e42487. PubMed ID: 22880001
[TBL] [Abstract][Full Text] [Related]
36. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs.
Carrington EM; Vikstrom IB; Light A; Sutherland RM; Londrigan SL; Mason KD; Huang DC; Lew AM; Tarlinton DM
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10967-71. PubMed ID: 20534453
[TBL] [Abstract][Full Text] [Related]
37. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
Mazumder S; Choudhary GS; Al-Harbi S; Almasan A
Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702
[TBL] [Abstract][Full Text] [Related]
38. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
Vandenberg CJ; Cory S
Blood; 2013 Mar; 121(12):2285-8. PubMed ID: 23341542
[TBL] [Abstract][Full Text] [Related]
39. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.
Stolz C; Hess G; Hähnel PS; Grabellus F; Hoffarth S; Schmid KW; Schuler M
Blood; 2008 Oct; 112(8):3312-21. PubMed ID: 18689543
[TBL] [Abstract][Full Text] [Related]
40. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
